Related Experiment Video
Updated: Jun 28, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Spironolactone in patients with resistant hypertension]
Enrique Rodilla1, José A Costa, Francisco Pérez-Lahiguera
1Unidad de Hipertensión Arterial y Riesgo Vascular, Servicio de Medicina Interna, Hospital de Sagunto, Agencia Valenciana de Salud, Puerto de Sagunto, Valencia, España.
Medicina Clinica
|October 22, 2008
Summary
Adding spironolactone effectively lowers blood pressure (BP) in patients with resistant hypertension (HTR). However, achieving BP control is more challenging for diabetic patients.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Resistant hypertension (HTR) affects patients with high blood pressure (BP) despite triple therapy.
- Effective management strategies for HTR are crucial for cardiovascular health.
Purpose of the Study:
- To evaluate the efficacy of spironolactone in patients with resistant hypertension.
- To identify predictors of successful BP control in this patient group.
Main Methods:
- Retrospective observational study of 95 HTR outpatients on at least 3 full-dose medications.
- Assessed BP changes after 4 months of spironolactone addition.
- Logistic regression analysis identified factors associated with BP control.
Main Results:
- Spironolactone significantly reduced mean systolic and diastolic BP by 29/12 mmHg (p=0.001).
- 38% of patients achieved BP control goals.
- Lower initial systolic BP (<165 mmHg) predicted better control (OR=3.97), while diabetes predicted poorer control (OR=0.33).
Conclusions:
- Spironolactone is an effective add-on therapy for lowering BP in HTR patients.
- Diabetic patients with HTR face greater challenges in achieving BP control.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...